Immune checkpoint inhibitors’ combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis Dianhe LiLing TangYan He Review 25 June 2022 Pages: 933 - 939
Anti-PD-1-based immunotherapy plus lenvatinib to treat advanced gallbladder cancer in the elderly: a case series and review of current literature Lantian WangKezhong TangWenjie Lu Review 27 June 2022 Pages: 941 - 950
Circulating metabolite biomarkers: a game changer in the human prostate cancer diagnosis Sabareeswaran KrishnanShruthi KanthajeChandrahas Koumar Ratnacaram Review 28 June 2022 Pages: 951 - 967
Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis Wen WenYong ZhangYingshuang Chen Review 30 June 2022 Pages: 969 - 978
Roles of circular RNAs in regulating the development of glioma Jianing FanYangyang WangYu Li Review 01 July 2022 Pages: 979 - 993
Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion Yongfeng ZhaoFuling Zhou Original Article – Clinical Oncology 25 February 2022 Pages: 995 - 1006
Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis T. StolzeS. FrankeM. Venerito Original Article – Clinical Oncology Open access 25 February 2022 Pages: 1007 - 1017
The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients Guowu WuLonghua GuoShifu Chen Original Article – Clinical Oncology Open access 26 February 2022 Pages: 1019 - 1028
Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo-)radiotherapy: a systematic review and meta-analysis Armando De VirgilioAndrea CostantinoGiuseppe Spriano Original Article – Clinical Oncology 02 March 2022 Pages: 1029 - 1041
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience Vittorio StefoniLisa ArgnaniPier Luigi Zinzani Original Article – Clinical Oncology Open access 03 March 2022 Pages: 1043 - 1047
Response prediction in patients with gastric and esophagogastric adenocarcinoma under neoadjuvant chemotherapy using targeted gene expression analysis and next-generation sequencing in pre-therapeutic biopsies Karsten KleoVladimir M. JovanovicSeverin Daum Original Article – Clinical Oncology Open access 05 March 2022 Pages: 1049 - 1061
Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis Shuwen ZhangJingjing ChenJian Feng Original Article – Clinical Oncology Open access 06 March 2022 Pages: 1063 - 1077
A virtual dance sport class for cancer patients: the trainer perspective Christian KeinkiIvonne RudolphJutta Hübner Original Article – Clinical Oncology Open access 07 March 2022 Pages: 1079 - 1083
A propensity score–matched analysis of breast-conserving surgery plus whole-breast irradiation versus mastectomy in breast cancer Francesca MagnoniGiovanni CorsoPaolo Veronesi Original Article – Clinical Oncology 07 March 2022 Pages: 1085 - 1093
Robotic stereotactic body radiotherapy for the management of adrenal gland metastases: a bi-institutional analysis Felix EhretDavid KaulAlexander Muacevic Original Article – Clinical Oncology Open access 15 March 2022 Pages: 1095 - 1101
Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer Wei DuChen ChenShaodong Hong Original Article – Clinical Oncology 18 March 2022 Pages: 1103 - 1113
Characteristics and survival of primary vaginal malignancy: an analysis of the German nationwide cancer registry data Dirk Michael Forner Original Article – Clinical Oncology 21 March 2022 Pages: 1115 - 1122
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer Yuki MatsubaraToshiki MasuishiKei Muro Original Article – Clinical Oncology 22 March 2022 Pages: 1123 - 1129
Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen Seung-Hoon BeomJong Gwang KimDong Han Kim Original Article – Clinical Oncology 27 March 2022 Pages: 1131 - 1143
A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome Courtney D. DiNardoAndreas HochhausAndrew H. Wei Original Article – Clinical Oncology 30 March 2022 Pages: 1145 - 1158
Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse Oliver HoffmannSebastian WormlandVera Rebmann Original Article – Clinical Oncology Open access 02 April 2022 Pages: 1159 - 1174
Correlation analysis between androgen receptor and the clinicopathological features and prognosis of mammary Paget’s disease Yang WuShanshan SunYanni Song Original Article – Clinical Oncology 02 April 2022 Pages: 1175 - 1184
Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study Hejing BaoLing Zhen MaShudong Ma Original Article – Clinical Oncology Open access 04 April 2022 Pages: 1185 - 1193
Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers O. OrtmannJ.-U. Blohmerfor 55 breast cancer centers certified by the German Cancer Society Original Article – Clinical Oncology Open access 05 April 2022 Pages: 1195 - 1209
Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC Xiao LiangWei ZhangRenhua Guo Original Article – Clinical Oncology 05 April 2022 Pages: 1211 - 1220
Can whole-body MRI replace CT in management of metastatic testicular cancer? A prospective, non-inferiority study Solveig Kärk Abildtrup LarsenVibeke LøgagerErik Morre Pedersen Original Article – Clinical Oncology 07 April 2022 Pages: 1221 - 1230
Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer Alina KrauseGertraud StockerMaren Knödler Original Article – Clinical Oncology Open access 08 April 2022 Pages: 1231 - 1240
Expression of DNA mismatch repair proteins in melanoma patients treated with immune checkpoint inhibitors T. GambichlerC. FinisL. Susok Original Article – Clinical Oncology Open access 13 April 2022 Pages: 1241 - 1247
Systemic inflammation with sarcopenia predicts survival in patients with gastric cancer Yu-Ying LiuGuo-Tian RuanHan-Ping Shi Original Article – Clinical Oncology 18 April 2022 Pages: 1249 - 1259
Gastric cancer in the pediatric population, a multicenter cross-sectional analysis of presentation and coexisting comorbidities Thomas M. AttardUraizee OmarMike A. Thomson Original Article – Clinical Oncology 18 April 2022 Pages: 1261 - 1272
KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer Keitaro ShimozakiEiji ShinozakiKensei Yamaguchi Original Article – Clinical Oncology 19 April 2022 Pages: 1273 - 1283
Antibiotic therapy is associated with an increased incidence of cancer Christoph RoderburgSven H. LoosenKarel Kostev Original Article – Clinical Oncology Open access 19 April 2022 Pages: 1285 - 1293
LncRNA UCA1 promoted cisplatin resistance in lung adenocarcinoma with HO1 targets NRF2/HO1 pathway Wenjing ShiLiqun LingYumin Wang Research 06 July 2022 Pages: 1295 - 1311
The survival analysis and feasibility study of Pars Plana Vitrectomy (PPV) in the treatment of retinoblastoma Jianing MouLei YangXin Ni Research 10 November 2022 Pages: 1313 - 1318
Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study Katharina KolbeIvonne HaffnerFlorian Lordick Research Open access 27 August 2022 Pages: 1319 - 1329
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal surface malignancies (PSM): a prospective single-center registry study B. Jansen-WinkelnJ. EberthR. Thieme Research Open access 13 December 2022 Pages: 1331 - 1341
Study protocol: the OptiScreen-Study: optimized psycho-oncological care—from screening to intervention Tanja ZimmermannLara DreismannArndt Vogel Research Open access 27 September 2022 Pages: 1343 - 1354
Correction: LncRNA UCA1 promoted cisplatin resistance in lung adenocarcinoma with HO1 targets NRF2/HO1 pathway Wenjing ShiLiqun LingYumin Wang Correction 03 January 2023 Pages: 1355 - 1355
Pembrolizumab for all Myung S. KimVinay Prasad Correspondence Open access 22 October 2022 Pages: 1357 - 1360
Patient characteristics and preferences for a surgical prehabilitation program design: results from a pilot survey Usha GurunathanOystein TronstadChristopher Stonell Correspondence 25 October 2022 Pages: 1361 - 1367
Reply to Letter to the Editor regarding “Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo‐)radiotherapy: a systematic review and meta‐analysis” Armando De VirgilioAndrea CostantinoGiuseppe Spriano Correspondence 29 October 2022 Pages: 1369 - 1371